New drug for menstrual cramps shows promise in early clinical trial

Mar 23, 2010
Painful menstrual cramps could be treated more effectively by a new drug now in clinical trials. Credit: iStock

Scientists today described the discovery of a new drug, which is currently in Phase II clinical trials, designed to specifically target the root cause of painful menstrual cramps, not just the symptoms. The condition, called dysmenorrhea, is the leading cause of absenteeism from school and work among women in their teens and 20s. The scientists described the study at the American Chemical Society (ACS) 239th National Meeting, being held here this week.

"We hope that the drug will provide a more effective treatment option for millions of women worldwide with this painful condition," said Andrzej R. Batt, "Dysmenorrhea not only diminishes the quality of life for millions of women, but also has a hidden, society-wide economic cost that involves an enormous number of days lost from work and school. Batt is with Vantia Ltd, a pharmaceutical company in the United Kingdom, which is developing and testing the drug.

Batt pointed out that dysmenorrhea affects between 45 and 90 percent of women of child-bearing age, In addition to pain in the abdomen and back, symptoms may include nausea, vomiting, sweating, and dizziness. Existing treatments for the condition include pain-relievers, anti-inflammatory drugs, and that stop menstruation. However,these treatments are ineffective in almost one-third of women with moderate to severe cases. Some of them relieve only the symptoms, rather than targeting the underlying cause of dysmenorrhea, and may have unwanted side effects such as mood alteration and stomach upsets.

Menstrual cramps are caused by contractions of the uterus during menstruation. In dysmenorrhea, the uterus contracts with increased frequency, causing unusually severe, cramping pain. The cause, scientists believe, is increased blood levels of the hormone , which plays a role in regulating contraction of the uterus. The Vantia scientists reasoned that blocking this hormone might relieve dysmenorrhea..

Their search for such a potential drug involved shifting through hundreds of chemical compounds and led to one with the desired effects. Scientists then re-engineered the compound, known by the code word ,VA111913, to fine-tune its effects. One modification allowed the drug to be administered orally, as a pill, rather than in an injection. They will reveal VA111913's molecular structure for the first time at the ACS meeting.

Batt said that last year VA111913 successfully passed a landmark toward becoming a new drug, when the first stage of clinical trials showed that it was safe for further clinical studies, with no apparent ill-effects. The next phase of clinical trials is currently underway in the U.K. and the U.S. (at sites in Peoria, Ariz.; Austin, Texas; and Salt Lake City) to evaluate how well it works to control pain in a group of women with dysmenorrhea. Investigators expect results to be available later this year. If studies continue to show promise, the drug could be available to patients in four years, the scientists say.

Explore further: India's meth addiction grows as criminals tap chemical hub

Provided by American Chemical Society

not rated yet
add to favorites email to friend print save as pdf

Related Stories

New study: Pine bark significantly reduces menstrual pain

Jun 18, 2008

A new study reveals dysmenorrhea, a condition that causes extremely painful menstrual periods affecting millions of women each year, can be reduced naturally by taking Pycnogenol (pic-noj-en-all), pine bark extract from the ...

Chinese herbs for endometriosis

Jul 08, 2009

Chinese herbal medicine (CHM) may relieve symptoms in the treatment of endometriosis. A systematic review by Cochrane Researchers found some evidence that women had comparable benefits following laparoscopic surgery and suffered ...

Welsh shingles drug set for final hurdle

Mar 23, 2010

A new Welsh-developed drug to help alleviate the suffering of shingles could move a step closer for patients if the final stage of testing is given the go-ahead.

Scientists identify possible cause of endometriosis

Aug 05, 2008

Endometriosis is a condition whereby patches of the inner lining of the womb appear in parts of the body other than the womb cavity. It can cause severe pain and affects approximately 15% of women of reproductive ...

Recommended for you

Determine patient preferences by means of conjoint analysis

Jul 29, 2014

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

User comments : 0